4//SEC Filing
McMurdo Matthew Charles 4
Accession 0000921895-23-001754
CIK 0000910267other
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 5:43 PM ET
Size
10.2 KB
Accession
0000921895-23-001754
Insider Transaction Report
Form 4
McMurdo Matthew Charles
Director
Transactions
- Award
Option to Purchase Common Stock
2023-06-29+25,000→ 25,000 totalExercise: $1.52Exp: 2022-08-15→ Common Stock (25,000 underlying) - Award
Common Stock
2023-07-26+50,000→ 50,000 total - Award
Option to Purchase Common Stock
2023-06-29+100,000→ 100,000 totalExercise: $1.31Exp: 2022-09-15→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
- [F2]The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.
- [F3]The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.
Documents
Issuer
TITAN PHARMACEUTICALS INC
CIK 0000910267
Entity typeother
Related Parties
1- filerCIK 0001943108
Filing Metadata
- Form type
- 4
- Filed
- Jul 27, 8:00 PM ET
- Accepted
- Jul 28, 5:43 PM ET
- Size
- 10.2 KB